Contineum Therapeutics Reports Positive Topline Phase 1b Data for PIPE-791 in Chronic Pain

On April 30, 2026, Contineum Therapeutics announced positive topline results from its exploratory Phase 1b trial of PIPE-791, a selective LPA1 receptor antagonist, for the treatment of chronic osteoarthritis pain (COAP) and chronic low back pain (CLBP). The randomized, double-blind, placebo-controlled crossover trial enrolled 43 patients and met its primary objective of safety and tolerability. PIPE-791 was well-tolerated with no serious adverse events; the most common side effects were headache and fatigue. Exploratory efficacy data showed that patients treated with a once-daily 10mg oral dose generally experienced numerically greater improvements in pain intensity compared to placebo, as measured by the Pain-Intensity Numerical Rating Scale (PI-NRS). Specifically, in the COAP cohort during Treatment Period 1, PIPE-791 showed a mean PI-NRS reduction of -1.60 compared to -1.27 for placebo. Supportive evidence from the Modified Knee Injury and Osteoarthritis Outcome Scale (KOOS) also suggested functional improvements. The company believes these findings support further clinical development of PIPE-791 for chronic pain, alongside its ongoing development for idiopathic pulmonary fibrosis.